DonaldZozMDFCCP
Pulmonology • Lebanon, OHInterstitial Lung Diseases
Sr. Clinical Program Leader - IPF/ILD Boehringer Ingelheim
Dr. Zoz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Remote
Lebanon, OH 45036
Education & Training
Vanderbilt University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
Ohio State University HospitalResidency, Internal Medicine, 2005 - 2008- Ohio State University College of MedicineClass of 2005
Certifications & Licensure
OH State Medical License 2006 - 2025
TN State Medical License 2008 - 2011- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Start of enrollment: 2014 Jun 09
- Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Start of enrollment: 2016 Jun 09
- Join now to see all
Publications & Presentations
PubMed
- 65 citationsTrial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser
The New England Journal of Medicine. 2022-06-09 - 100 citationsEfficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSC...Kristin B. Highland, Oliver Distler, Masataka Kuwana, Yannick Allanore, Shervin Assassi
The Lancet. Respiratory Medicine. 2021-01-01 - 5 citationsPhase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.Toby M Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F Zoz
ERJ Open Research. 2022-10-01
Press Mentions
First Patient Enrolled in Phase 3 Trial Testing BI 1015550October 28th, 2022- Boehringer Enrols First Subject in Idiopathic Pulmonary Fibrosis TrialOctober 27th, 2022
Systemic Sclerosis (Scleroderma): Nintedanib Slowed Loss of Pulmonary FunctionMay 30th, 2019
Professional Memberships
- Member
- Fellow
Industry Relationships
- Director - Clinical Development & Medical Affairs - Respiratory IPF/ILD, Boehringer Ingelheim Pharmaceuticals, Inc2017 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
